Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
复制标题
DOI：
10.1093/annonc/mdx219
复制
发表时间：
2017-07-01
影响因子：
50.5
通讯作者：
Buske, C.
中科院分区：
文献类型：
--
作者：
Hochhaus, A.;Saussele, S.;Buske, C.
慢性髓性白血病（CML）的发病率在10至15例/年之间，没有任何主要的地理或种族差异。在欧洲，诊断时的中位年龄在60至65岁之间，但在人口较年轻的国家，这一年龄要低得多。CML的患病率正在稳步上升，因为靶向治疗已经大大延长了患者的生存期。儿童慢性粒细胞白血病是罕见的；儿科患者的生物学和治疗策略揭示了特定的方面。因此，这些建议主要适用于成人患者。
The incidence of chronic myeloid leukaemia (CML) ranges between 10 and 15 cases/10 6/year without any major geographic or ethnic differences [1]. The median age at diagnosis ranges between 60 and 65 years in Europe, but is considerably lower in countries with a younger population. The prevalence of CML is steadily rising due to the substantial prolongation of survival that has been achieved with targeted therapy [2]. CML in children is rare; biology and treatment strategies in paediatric patients reveal specific aspects [3]. Therefore, these recommendations are primarily intended for use in adult patients.